Emerging Research in Prostate Cancer Imaging — September 2024

News
Slideshow

Catch up on the most-well viewed prostate imaging content in September 2024.

Touching on a variety of topics in prostate cancer imaging, ranging from Phase 3 trial results for 177Lu-PSMA-617 in taxane-naïve patients with mCRPC to a new meta-analysis comparing PSMA PET/CT to mpMRI in detecting biomechanical recurrence of PCa, here are the top five most well-viewed prostate imaging content from Diagnostic Imaging for September 2024.

Recent Videos
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
Detecting PCa Recurrence in African Americans: Can 18F-Flotufolastat Have an Impact?
Related Content
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC

Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC

Jeff Hall
March 28th 2025
Article

Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).

The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET

The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET

Jeff Hall
March 18th 2025
Podcast

In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.

Could Microultrasonography-Guided Biopsy be an Alternative to MRI for PCa Detection in Biopsy-Naïve Men?

Could Microultrasonography-Guided Biopsy be an Alternative to MRI for PCa Detection in Biopsy-Naïve Men?

Jeff Hall
March 24th 2025
Article

Microultrasonography-guided biopsy offered comparable detection as MRI/conventional ultrasound-guided biopsy in detection of Gleason grade group 2 or higher prostate cancer, according to a new international multicenter study.

MindMoments: Consensus MRI Guidelines for Multiple Sclerosis

MindMoments: Consensus MRI Guidelines for Multiple Sclerosis

Matt Hoffman
July 3rd 2021
Podcast

An interview with two experts to discuss newly released guidance for using standardized MRI protocols for patients with this condition.

PSMA PET Prep Product Gozellix Garners FDA Approval

PSMA PET Prep Product Gozellix Garners FDA Approval

Jeff Hall
March 21st 2025
Article

Indicated for use in cases involving suspected metastasis with PCa or suspected PCa recurrence due to elevated PSA level, Gozellix reportedly has a longer shelf life than other gallium-based PET imaging products.

New Meta-Analysis Assesses Use of the Kaiser Score for Breast MRI

New Meta-Analysis Assesses Use of the Kaiser Score for Breast MRI

Jeff Hall
March 20th 2025
Article

The Kaiser score offers 24 percent higher pooled specificity than the Breast Imaging Reporting and Data System (BI-RADS) for detecting malignancies on breast MRI, according to a 29-study meta-analysis.

© 2025 MJH Life Sciences

All rights reserved.